首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
admin
2013-11-29
113
问题
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea: the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy, diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. "We’ve been too rigid in not making lifesaving drugs available to people who otherwise face certain death," says Representative Henry Waxman, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’s true of AIDS, but it’s also true of cancer and other life- threatening diseases."
For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story: a crisis—AIDS—helped crystallize an informal coalition for reform.
AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Do, g Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs—those that show new promise in treating serious or life-threatening diseases— had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it pro- posed died in Congress. Complaints were compounded by growing concern that "if we didn’t streamline policies, red tape wot, Id be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
Young was a key figure in the overhaul of the FDA’s policies. A pioneer in biotechnology and a former dean of the University of Rochester’s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology-- whose promise he had seen in his own gene-cloning lab--and to get experimental medicines to desperately iii people more quickly. He had seen people die waiting for new medicines because "they were in the wrong place at the wrong time," he said. That is now changing.
It can be said that the people who first started the quiet drug revolution are ______.
选项
A、doctors
B、government officials
C、AIDS patients
D、pharmacologists
答案
C
解析
转载请注明原文地址:https://www.kaotiyun.com/show/lHhO777K
0
考博英语
相关试题推荐
AmericaLosesaGreatPublicThinkerArthurMiller’sdeathlastweekmeantmorethanthelossofanoutstandingplaywright.
ThedomesticeconomyintheUnitedStatesexpandedinaremarkablyvigorousandsteadyfashion.Therevivalinconsumerconfiden
Thelawofprivateinternationaltribunalswithrespecttoconflictsofinterestofarbitratorsisquiteextensive,albeitbyno
Themarveloustelephoneandtelevisionnetworkthathasnowenmeshedthewholeworld,makingallmenneighbors,cannotbeextend
InmostSouthAmericancountriesrailtransportisplaguedbyoperationalproblemsaswellasbyobsoleteequipment.
Youheartherefrainallthetime:theU.S.economylooksgoodstatistically,butitdoesn’tfedgood.Whydoesn’tever-greater
Governmenthastraditionallybeenevaluatedintermsoftheireffectsinpromotingseveralprinciples.Wehaveseenthatoneof
BetweentheinventionofagricultureandthecommercialrevolutionthatmarkedtheendoftheMiddleAges,wealthandtechnology
InTheDisunitingofAmerica:ReflectionsonaMulticulturalSociety,RevisedandEnlargedEdition(W.W.Norton)Schlesingerpr
Anestheticsaresubstances____todeadenpainorproduceaconditioninwhichsomeorallofthesenses,especiallytouch,stopfun
随机试题
给定程序MODI1.C中函数fun的功能是:从n(形参)个学生的成绩中统计出低于平均分的学生人数,此人数由函数值返回,平均分存放在形参aver所指的存储单元中。例如,若输入8名学生的成绩:80.5607290.59851.5
公司在有多余现金时,向股东回购自己的股票,以此来代替现金股利指的是()
下列有关缺铁性贫血治疗的叙述,错误的是
脊髓灰质炎病毒主要侵犯下列哪一个部位
甲型强心苷元的母核结构称为()
下列项目中,属于长期资产的有()。
企业战略是指企业为了适应未来环境的变化,寻求长期生存和稳定发展而制定的()的谋划与方略。
教师职业道德的调节功能仅仅作用于教师本身。()
对于向乡镇企业非法收费、摊派、罚款的,企业有权向什么单位控告、检举?()
直接调控方式是指国家主要运用经济手段,通过市场机制,影响和引导企业的经济行为,以达到宏观管经济调控的目标。()
最新回复
(
0
)